Switch theme
Sign up to access all valuation multiples
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
2017
125
LTM Revenue $120M
LTM EBITDA $5.4M
$202M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Maze Therapeutics has a last 12-month revenue of $120M and a last 12-month EBITDA of $5.4M.
In the most recent fiscal year, Maze Therapeutics achieved revenue of $168M and an EBITDA of $60.9M.
Maze Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Maze Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $168M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$94.5M | $60.9M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | 36% | XXX | XXX | XXX |
| Net Profit | -$115M | -$100M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -60% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Maze Therapeutics's stock price is $8.
Maze Therapeutics has current market cap of $372M, and EV of $202M.
See Maze Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $202M | $372M | XXX | XXX | XXX | XXX | $0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Maze Therapeutics has market cap of $372M and EV of $202M.
Maze Therapeutics's trades at 1.7x LTM EV/Revenue multiple, and 37.1x LTM EBITDA.
Analysts estimate Maze Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Maze Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $202M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 3.3x | XXX | XXX | XXX |
| P/E | 7.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 2.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMaze Therapeutics's NTM/LTM revenue growth is -98%
Maze Therapeutics's revenue per employee for the last fiscal year averaged $1.3M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Maze Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Maze Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Maze Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -164% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -62% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 50% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 66% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Maze Therapeutics acquired XXX companies to date.
Last acquisition by Maze Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Maze Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Maze Therapeutics founded? | Maze Therapeutics was founded in 2017. |
| Where is Maze Therapeutics headquartered? | Maze Therapeutics is headquartered in United States of America. |
| How many employees does Maze Therapeutics have? | As of today, Maze Therapeutics has 125 employees. |
| Who is the CEO of Maze Therapeutics? | Maze Therapeutics's CEO is Dr. Jason V. Coloma, PhD. |
| Is Maze Therapeutics publicy listed? | Yes, Maze Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Maze Therapeutics? | Maze Therapeutics trades under MAZE ticker. |
| When did Maze Therapeutics go public? | Maze Therapeutics went public in 2025. |
| Who are competitors of Maze Therapeutics? | Similar companies to Maze Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Maze Therapeutics? | Maze Therapeutics's current market cap is $372M |
| What is the current revenue of Maze Therapeutics? | Maze Therapeutics's last 12-month revenue is $120M. |
| What is the current EBITDA of Maze Therapeutics? | Maze Therapeutics's last 12-month EBITDA is $5.4M. |
| What is the current EV/Revenue multiple of Maze Therapeutics? | Current revenue multiple of Maze Therapeutics is 1.7x. |
| What is the current EV/EBITDA multiple of Maze Therapeutics? | Current EBITDA multiple of Maze Therapeutics is 37.1x. |
| Is Maze Therapeutics profitable? | Yes, Maze Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
